Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
XP showed significant noninferiority for PFS versus FP in the first-line treatment of AGC and can be considered an effective alternative to FP.
[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or…
Intratumoral H101 injection showed a distinct efficacy in patients with squamous cell cancer of head and neck or esophagus, and was relatively safe.
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with mCRC and clinical benefit and safety profiles were consistent with those observed in pivotal phase III trials with mainly Caucasian patients.
[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].
- Jinwan Wang, Yan Sun, C. Yao
- Medicine, BiologyZhongguo fei ai za zhi = Chinese journal of lung…
- 20 August 2005
The addition of YH-16 to NP regimen results in significantly and clinically meaningful improvement in response rate, median time to tumor progression, and clinical benefit rate compared with NP alone in advanced NSCLC patients.
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
It is demonstrated that lapatinib combined with paclitaxel offers a significant and clinically meaningful survival advantage over paclitAXel alone in patients with newly diagnosed HER2-positive MBC.
High incidence of hepatitis B virus infection in B‐cell subtype non‐Hodgkin lymphoma compared with other cancers
The authors investigated the prevalence of hepatitis B virus (HBV) infection by using serologic markers in non‐Hodgkin lymphoma (NHL) compared with other types of cancers in Chinese patients.
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma
The objective of the current study was to assess the value of antiviral lamivudine for reducing the incidence and severity of hepatitis in HBV carriers with lymphoma who receive chemotherapy.
Superior efficacy of a Cremophor‐free albumin‐bound paclitaxel compared with solvent‐based paclitaxel in Chinese patients with metastatic breast cancer
The aim of the present randomized study was to compare the response rates and safety profile of nab‐paclitaxel with sb‐pac litaxel in Chinese patients with MBC.